A systematic review of coverage decision-making on health technologies-Evidence from the real world

被引:39
|
作者
Fischer, Katharina Elisabeth [1 ,2 ]
机构
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, D-20354 Hamburg, Germany
[2] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Hlth Econ & Hlth Care Management, D-85764 Neuherberg, Germany
关键词
Fourth hurdle; Reimbursement; Resource allocation; Pharmaceutical; Drug formulary; Quantitative methods; COST-EFFECTIVENESS THRESHOLD; CLINICAL-EXCELLENCE; NATIONAL-INSTITUTE; ECONOMIC EVALUATIONS; CANCER DRUGS; 4TH HURDLE; NICE; REIMBURSEMENT; AUSTRALIA; SUBMISSIONS;
D O I
10.1016/j.healthpol.2012.07.005
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: Quantitative analysis of real-world coverage decision-making offers insights into the revealed preferences of appraisal committees. Aim of this review was to structure empirical evidence of coverage decisions made in practice based on the components 'methods and evidence', 'criteria and standards', 'decision outcome' and 'processes'. Methods: Several electronic databases, key journals and decision committees' websites were searched for publications between 1993 and June 2011. Inclusion criteria were the analysis of past decisions and application of quantitative methods. Each study was categorized by the scope of decision-making and the components covered by the variables used in quantitative analysis. Results: Thirty-two studies were identified. Many focused on pharmaceuticals, the UK NICE or the Australian PBAC. The components were covered comprehensively, but heterogeneously. Seventy-two variables were identified of which the following were more prevalent: specifications of the decision outcome; the indications considered for appraisal, identification of incremental cost-effectiveness ratios, appropriateness of evaluation methods, type of economic or clinical evidence used for assessment, and the decision date. Conclusions: Research was dominated by analysis of decision outcomes and appraisal criteria. Although common approaches were identified, the complexity of coverage decision-making - reflected by the heterogeneity of identified variables - will continue to challenge empirical research. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:218 / 230
页数:13
相关论文
共 50 条
  • [1] Costing evidence for health care decision-making in Austria: A systematic review
    Mayer, Susanne
    Kiss, Noemi
    Laszewska, Agata
    Simon, Judit
    [J]. PLOS ONE, 2017, 12 (08):
  • [2] To Fund or Not to FundDevelopment of a Decision-Making Framework for the Coverage of New Health Technologies
    Tania Stafinski
    Devidas Menon
    Christopher McCabe
    Donald J. Philippon
    [J]. PharmacoEconomics, 2011, 29 : 771 - 780
  • [3] Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Hukkelhoven, Mathias
    Rockhold, Frank
    O'Donnell, John
    [J]. CLINICAL THERAPEUTICS, 2022, 44 (03) : 420 - 437
  • [4] DECISION-MAKING IN REAL WORLD
    HOLLANDER, GL
    [J]. IEEE TRANSACTIONS ON SYSTEMS MAN AND CYBERNETICS, 1972, SMC2 (02): : 275 - +
  • [5] Real world evidence for public health decision-making on vaccination policies: perspectives from an expert roundtable
    de Waure, Chiara
    Gartner, Barbara C.
    Lopalco, Pier Luigi
    Puig-Barbera, Joan
    Nguyen-Van-Tam, Jonathan S.
    [J]. EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 27 - 38
  • [6] Real-world evidence for regulatory decision-making: updated guidance from around the world
    Burns, Leah
    Le Roux, Nadege
    Kalesnik-Orszulak, Robert
    Christian, Jennifer
    Dudinak, Jennifer
    Rockhold, Frank
    Khozin, Sean
    O'Donnell, John
    [J]. FRONTIERS IN MEDICINE, 2023, 10
  • [7] To Fund or Not to Fund Development of a Decision-Making Framework for the Coverage of New Health Technologies
    Stafinski, Tania
    Menon, Devidas
    McCabe, Christopher
    Philippon, Donald J.
    [J]. PHARMACOECONOMICS, 2011, 29 (09) : 771 - 780
  • [8] DOES REAL-WORLD EVIDENCE PLAY A ROLE IN DECISION-MAKING BY HTA BODIES FOR MEDICAL TECHNOLOGIES?
    Hartley, L.
    Gildea, L.
    Mordin, M.
    Long, J.
    D'Souza, V
    Kinderas, M.
    Ling, C.
    Warttig, S.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S434 - S435
  • [9] The use of evidence in English local public health decision-making: a systematic scoping review
    Kneale, Dylan
    Rojas-Garcia, Antonio
    Raine, Rosalind
    Thomas, James
    [J]. IMPLEMENTATION SCIENCE, 2017, 12
  • [10] The use of evidence in English local public health decision-making: a systematic scoping review
    Dylan Kneale
    Antonio Rojas-García
    Rosalind Raine
    James Thomas
    [J]. Implementation Science, 12